A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Javid J. Moslehi et al.|Clinical Cancer Research|2024Cited by 50
Supplementary Table S1 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Sagar Lonial et al.|Unknown|2024Cited by 1
Data from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Sagar Lonial et al.|Unknown|2024Cited by 0
Supplementary Table S2 from A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic MalignanciesPinkal Desai, James S. Blachly, Marcio Andrade‐Campos et al.|Unknown|2024Cited by 0